Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Till Kasch

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|September 5, 2024
Development of Tailless Homologue Receptor (TLX) Agonist Chemical ToolsEmily C Hank, Minh Sai, Till Kasch, et al.
Journal of Medicinal Chemistry|September 18, 2025
Development of Potent and Selective Dual PPARδ/sEH Modulators from an AI-Designed ScaffoldXiu Ge, Till Kasch, Max Lewandowski, et al.
Journal of Medicinal Chemistry|July 24, 2025
Development of an RXR Agonist Scaffold with Pronounced Homodimer PreferenceFelix Nawa, Arthur Kardanov, Till Kasch, et al.
Communications Chemistry|July 1, 2024
Development of Nurr1 agonists from amodiaquine by scaffold hopping and fragment growingMinh Sai, Emily C Hank, Hin-Man Tai, et al.
Journal of Medicinal Chemistry|November 24, 2025
Structural Tuning of Partial RXR Agonism and AntagonismMax Lewandowski, Marie Granger-Rivière, Domenic Mayer, et al.
Journal of Medicinal Chemistry|June 3, 2026
An Activator of Tailless' Repressor Function Stimulates Anti-Neurodegenerative Gene ExpressionEmily C Hank, Romy Busch, Úrsula López-García, et al.
Journal of Medicinal Chemistry|January 18, 2024
Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical PropertiesMax Lewandowski, Melania Carmina, Loris Knümann, et al.
Journal of Medicinal Chemistry|December 8, 2023
Structural Fusion of Natural and Synthetic Ligand Features Boosts RXR Agonist PotencyGustave Adouvi, Felix Nawa, Marco Ballarotto, et al.
Journal of Medicinal Chemistry|July 31, 2024
Structural Optimization of Oxaprozin for Selective Inverse Nurr1 AgonismSabine Willems, Romy Busch, Felix Nawa, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|September 5, 2024
Development of Tailless Homologue Receptor (TLX) Agonist Chemical ToolsEmily C Hank, Minh Sai, Till Kasch, et al.
Journal of Medicinal Chemistry|September 18, 2025
Development of Potent and Selective Dual PPARδ/sEH Modulators from an AI-Designed ScaffoldXiu Ge, Till Kasch, Max Lewandowski, et al.
Journal of Medicinal Chemistry|July 24, 2025
Development of an RXR Agonist Scaffold with Pronounced Homodimer PreferenceFelix Nawa, Arthur Kardanov, Till Kasch, et al.
Communications Chemistry|July 1, 2024
Development of Nurr1 agonists from amodiaquine by scaffold hopping and fragment growingMinh Sai, Emily C Hank, Hin-Man Tai, et al.
Journal of Medicinal Chemistry|November 24, 2025
Structural Tuning of Partial RXR Agonism and AntagonismMax Lewandowski, Marie Granger-Rivière, Domenic Mayer, et al.
Journal of Medicinal Chemistry|June 3, 2026
An Activator of Tailless' Repressor Function Stimulates Anti-Neurodegenerative Gene ExpressionEmily C Hank, Romy Busch, Úrsula López-García, et al.
Journal of Medicinal Chemistry|January 18, 2024
Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical PropertiesMax Lewandowski, Melania Carmina, Loris Knümann, et al.
Journal of Medicinal Chemistry|December 8, 2023
Structural Fusion of Natural and Synthetic Ligand Features Boosts RXR Agonist PotencyGustave Adouvi, Felix Nawa, Marco Ballarotto, et al.
Journal of Medicinal Chemistry|July 31, 2024
Structural Optimization of Oxaprozin for Selective Inverse Nurr1 AgonismSabine Willems, Romy Busch, Felix Nawa, et al.
Pageof 1